الفهرس 
Effect of Certain monoclonal antibodies as inhibitors of epidermal growth factor (EGF) family receptors on different cancer cell lines
Arabic CoverOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Colorectal cancer is considered to be one of the major causes of cancer-related deaths in the world. Cetuximab
and panitumumab are FDA approved epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies
that used for treatment of metastatic colorectal cancer (mCRC) are interacting with the binding site of EGFR to
block ligand stimulation olon cancer. Bee Venom has inhibitory effect on several types of cancer. the current
study aimed to compare the cytotoxic effect of cetuximab and panitumumab on two colon cancer cell lines
(HCT116 and Caco-2) to identify the most cytotoxic mAb and to assess the synergistic effects of cetuximab and
bee venom on 2 colon cancer cell lines to obtain the lowest lethal concentrations of this monoclonal antibody
.MTT assay was used to investigate the cytotoxic effect of cetuximab , panitumumab, bee venom and synergistic
effect between cetuximab and BV. Flow cytometry analysis was used to look at cell cycle distribution and
apoptosis induction. RT-PCR can identify changes in apoptotic genes expression. The results show that IC50 of
cetuximab and pantiumumab against two cell lines (HCT 116 and Caco-2) were 740µg/ml and 686 µg/ml for
cetuximab and 3298 µg/ml and 2463for pantiumumab respectively.BV has IC50 against Caco-2 and HCT-116
(10.5 g/ml and 13 g/ml respectively). Combination treatment had a synergistic inhibitory impact on two cell
lines (CI< 1), according to the results. Both cell lines were arrested in the G2/M phase of the cell cycle. In
addition, when combination therapy was used instead of cetuximab alone, apoptosis was dramatically increased
in both cell lines. In addition, after treatment with (Ce/BV), Bcl-2 and p53 were shown to be down regulated
and up regulated, respectively, in two cell lines. As a result, the combination of cetuximab and BV showed
preclinical efficacy in the treatment of colon cancer